We own and operate 14 manufacturing facilities across five locations in India and two manufacturing facilities in the United States. In order to serve our domestic and international markets, we own and operate formulation and API manufacturing facilities which have been built in accordance with the WHO cGMP guidelines. Each of our manufacturing facilities has separate quality control units to monitor the manufacturing quality of our products. Of the 14 facilities, our facilities at Ankleshwar and Mandwa are API manufacturing facilities. The remaining facilities, including those at Daman, Baddi and Sikkim, manufacture formulations.
Our manufacturing facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities including the US FDA, World Health Organization (WHO), MHRA (UK), TGA (Australia), ANVISA (Brazil) and MCC (South Africa).
In line with our quality policy, we have set up quality functions across the organization to consistently monitor the process operations for assuring the quality, safety and efficacy of our products in the domestic and export markets. Our Quality Management Systems (QMS) complies with various international regulatory and cGMP standards and we perform periodic reviews of systems, practices and documentation in place across our manufacturing facilities through regular audits.
All products are subjected to extensive stability testing programs to understand the real product behaviour during shelf life. We also monitor in-market product quality through annual product quality review mechanisms.
We believe that all our manufacturing facilities possess adequate effluent treatment processes and minimize any contamination of the surrounding environment or pollution. All these environment protection systems are laid down as per the statutory requirements of applicable laws and environmental policies.
To view the state-of the art manufacturing facilities, click here